Immunostimulatory bacteria for the treatment of cancer
Inventors
Anker, Jonathan F. • Thumbikat, Praveen • Abdulkadir, Sarki A. • Schaeffer, Anthony J.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.
Core Innovation
The document describes compositions and engineered Escherichia coli (E. coli) strain CP1 bacteria (ATCC Patent Deposit #PTA-127513) for use against prostate cancer. CP1 homes to prostate tumors and can adhere, invade, and proliferate in prostate cancer cells, with whole-genome characterization and comparison to MG1655 reported in the document.
The document further states that CP1 induces immunogenic cell death (ICD) and releases danger-associated molecular patterns (DAMPs), including HMGB1, ATP, and calreticulin. It also states that CP1 shifts the prostate tumor microenvironment toward a pro-inflammatory, anti-tumor phenotype, with increased tumor-infiltrating lymphocytes (TILs) such as Th1/Th17, increased CD8 cytotoxic activity, and increased mature dendritic cells and M1 macrophages, together with increased NK, γδ T cells, and B cells.
In addition, the document states that CP1 decreases immunosuppressive elements including Tregs and MDSCs, and decreases VEGF and IL-6. It reports that CP1 shows synergy with anti-PD-1 therapy, improves survival and reduces tumor burden versus monotherapies, and that T-cell recruitment dependence is shown using FTY720; it also reports extension of efficacy to a CRPC-like PTEN-knockout Myc-CaP orthotopic model.
Claims Coverage
The independent claim set includes one independent composition claim. The main inventive features across the independent claim are directed to a genetically engineered CP1 E. coli composition that displays tumor-associated antigens.
Genetically engineered CP1 E. coli displaying tumor-associated antigens
A composition comprising Escherichia coli strain CP1 bacteria (ATCC Patent Deposit #PTA-127513) that is genetically engineered to display one or more tumor-associated antigens.
Across the independent claim coverage provided, the invention is centered on a composition of genetically engineered CP1 E. coli (ATCC Patent Deposit #PTA-127513) configured to display one or more tumor-associated antigens, with dependent claim refinements further specifying antigens and co-therapy with immune checkpoint inhibitors.
Stated Advantages
Induces immunogenic cell death (ICD) with DAMPs (HMGB1, ATP, calreticulin).
Shifts the prostate tumor microenvironment toward a pro-inflammatory, anti-tumor phenotype with increased TILs and immune activation.
Decreases immunosuppressive elements including Tregs and MDSCs.
Decreases VEGF and IL-6.
Synergy with anti-PD-1 therapy, improving survival and reducing tumor burden.
Extends efficacy to a CRPC-like PTEN-knockout Myc-CaP orthotopic model.
Documented Applications
Treatment of prostate cancer using CP1 E. coli that homes to prostate tumors, induces immunogenic cell death, and modulates the prostate tumor microenvironment.
Combined treatment with anti-PD-1 therapy, where synergy is reported to improve survival and reduce tumor burden.
Use of T-cell recruitment dependence assessed using FTY720.
Efficacy assessment in a CRPC-like PTEN-knockout Myc-CaP orthotopic model.
Engineering CP1 to express tumor-associated antigens, including PSA and PSCA (with hPSCA and mPSCA mentioned) for antigen-specific T-cell responses.
Interested in licensing this patent?